Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05285813 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
A Phase 2 study of AML and MDS, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT05285813 is a Phase 2 study of AML and MDS that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 42 participants, below the 132-participant average among 29 other AML trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05285813, a Phase 2 study of AML and MDS, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II single-center study to evaluate the safety and effectiveness of vibecotamab, a CD3-CD123 bispecific antibody, in patients with acute myeloid leukemia with persistent or recurrent measurable residual disease and in patients with myelodysplastic syndrome that has not responded to or relapsed after conventional therapy
Interventions
- DRUG Acetaminophen
- DRUG Dexamethasone
- DRUG Diphenhydramine
- DRUG Vibecotamab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-05-06 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05285813
The ClinicalTrials.gov registry entry for NCT05285813 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 29 other AML trials with a reported enrollment target (68% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with AML appearing as the primary indexed condition, and to 4 interventions - of which Acetaminophen is the first listed.
NCT05285813 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05285813 about?
NCT05285813 is a clinical study titled "A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure". This is a phase II single-center study to evaluate the safety and effectiveness of vibecotamab, a CD3-CD123 bispecific antibody, in patients with acute myeloid leukemia with persistent or recurrent measurable residual disease and in patients with myelodysplastic syndrome that has not responded to or...
What is the current status of trial NCT05285813?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2022-05-06. Estimated completion is 2026-12-31.
What conditions does trial NCT05285813 study?
This clinical trial studies the following conditions: AML, MDS.
What interventions are being tested in trial NCT05285813?
The interventions under investigation include: Acetaminophen (DRUG), Dexamethasone (DRUG), Diphenhydramine (DRUG), Vibecotamab (DRUG).
Who is sponsoring clinical trial NCT05285813?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05285813 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AML
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
RECRUITING · Phase 2
-
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
RECRUITING · Phase 2
-
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
RECRUITING · Phase 2
-
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
RECRUITING · Phase 2
-
Cardioprotection in AML
RECRUITING · Phase 2
-
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.